PREZISTAPREZCOBIXREZOLSTASYMTUZA — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson PREZISTAPREZCOBIXREZOLSTASYMTUZA — Sales to customers (Note 9) remained flat by 0.0% to $793.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 11.7%, from $898.00M to $793.00M. Over 2 years (FY 2021 to FY 2024), PREZISTAPREZCOBIXREZOLSTASYMTUZA — Sales to customers (Note 9) shows a downward trend with a -11.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and sustained demand for the product line, while a decrease may signal increased generic competition or a shift in treatment standards.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific portfolio of HIV antiviral medication...
Peer comparison
Comparable to revenue reporting for specific therapeutic drug franchises or product lines in other major pharmaceutical companies.
jnj_segment_prezista_prezcobix_rezolsta_symtuza_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.09B | $1.01B | $1.03B | $1.27B | $1.00B | $929.00M | $969.00M | $954.00M | $894.00M | $836.00M | $876.00M | $898.00M | $814.00M | $806.00M | $793.00M | $793.00M |
| QoQ Change | — | -7.5% | +2.4% | +22.4% | -20.9% | -7.3% | +4.3% | -1.5% | -6.3% | -6.5% | +4.8% | +2.5% | -9.4% | -1.0% | -1.6% | +0.0% |
| YoY Change | — | — | — | — | -8.2% | -8.0% | -6.3% | -4.8% | -3.8% | — | -8.2% | +0.4% | — | -3.6% | -9.5% | -11.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's prezistaprezcobixrezolstasymtuza — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported prezistaprezcobixrezolstasymtuza — sales to customers (note 9) of $793.00M in Q3 2025.
- How has Johnson & Johnson's prezistaprezcobixrezolstasymtuza — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's prezistaprezcobixrezolstasymtuza — sales to customers (note 9) decreased by 11.7% year-over-year, from $898.00M to $793.00M.
- What is the long-term trend for Johnson & Johnson's prezistaprezcobixrezolstasymtuza — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's prezistaprezcobixrezolstasymtuza — sales to customers (note 9) has grown at a -11.5% compound annual growth rate (CAGR), from $4.37B to $3.42B.
- What does prezistaprezcobixrezolstasymtuza — sales to customers (note 9) mean?
- The total revenue generated from the sale of a specific group of HIV treatment medications.